Fibrin sealant - OMRIX

Drug Profile

Fibrin sealant - OMRIX

Alternative Names: Adhexil

Latest Information Update: 01 Oct 2015

Price : $50

At a glance

  • Originator OMRIX Biopharmaceuticals
  • Class Antihaemorrhagics; Blood coagulation factors; Blood proteins; Serine endopeptidases
  • Mechanism of Action Fibrinogen replacements; Thrombin replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Post-surgical adhesions

Most Recent Events

  • 01 Oct 2015 No recent reports of development identified - Phase-III for Post-surgical adhesions in Russia, Mexico, European Union and USA (Topical)
  • 30 Dec 2008 OMRIX Biopharmaceuticals has been acquired by Johnson and Johnson
  • 25 Oct 2007 Phase I/II clinical trials in Post-surgical adhesions in European Union (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top